The ANGLE Team

Garth Selvey

Garth Selvey

Non Executive Chairman

Garth Selvey has a BSc in Physics and Electronics Engineering from the University of Manchester and has spent thirty six years in the computer industry with technical, product, sales and marketing roles. He became Managing Director of TIS Applications Ltd in 1984 and a main board director of TIS Ltd prior to its acquisition by Misys in 1989. He organised the management buyout of the social housing division of Misys and became Group Chief Executive of Comino Group plc when it floated on AIM in 1997. Comino moved to a full listing in 1999 where he remained until its successful public sale to Civica plc in February 2006. Garth joined ANGLE as a Non-executive Director in September 2006.


Andrew Newland

Andrew Newland

Chief Executive

Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant. After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he led KPMG’s involvement in the IPO of the medical technology
company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG’s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in 1994. Together with ANGLE’s senior management team, Andrew has co-founded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of dstl Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.


Ian Griffiths

Ian Griffiths

Finance Director

Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work. He joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures, both third party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic business Parsortix.


Brian Howlett

Brian Howlett

Non Executive Director

Brian Howlett has a wealth of international experience as a medtech leader which he is currently applying in a Non-Executive / Chairman capacity for surgical graft company Vascular Flow Technologies Ltd, skin cancer imaging company Michelson Diagnostics Ltd and medical device coating and surface modification company Accentus Medical Ltd, as well as ANGLE plc. Brian was formerly CEO of Lombard Medical Technologies PLC, an AIM listed company specialising in stents for abdominal aortic aneurysms from 2005 to 2009. During his tenure significant capital was raised to fund the development of operations to commercialise the Aorfix stent graft towards regulatory approvals and growing revenues in EU, USA, Russia and Brazil. Corporate experience includes six years as UK Country Leader of Boston Scientific Ltd, between 1999 and 2005, during which time major medical devices such as the TAXUS drug eluting stent were launched driving sales and profits to the point where the UK and Ireland subsidiary became one of the leading revenue contributors to the Corporation’s European operations. Between 1987 and 1999, Brian was Managing Director of the UK sales and manufacturing subsidiary of Cobe Laboratories Inc. In addition, Brian spent almost 20 years in the pharmaceutical industry, gaining strong sales and marketing experience through a number of senior management positions in UK, Scandinavia and the Benelux markets within Fisons plc. Brian joined ANGLE as a Non-executive Director in January 2013.


Dr. Daniel Danila

Dr. Daniel Danila is an assistant attending physician at Memorial Hospital Cancer Center in New York. He also serves as an instructor with the Weill Cornell Medical College. Dr Danila’s primary research focuses on prostate cancer. Specifically, he is exploring a hypothesis that molecular profiling of circulating tumour cells (CTCs) can be used to assess biological determinants of the growth of prostate cancer tumours.

Most recently, Dr. Danila served as the principal investigator (PI) for “Circulating Tumor Cells as Biomarkers for Patients with Metastatic Prostate Cancer: Developing Assays for Androgen Receptor Signaling Pathway,” which focused on analysing CTCs from patients with metastatic prostate cancer for molecular biomarkers predictive of tumor sensitivity to targeted treatments. Funding for the research was provided by the Department of Defense Congressionally Directed Medical Research Programs, Prostate Cancer Research Program, Physician Research Training Award.

Danila received his MD from Carol Davila University of Medicine and Pharmacy in Bucharest, Romania and was a research fellow, intern and resident at Massachusetts General Hospital prior to joining Memorial Sloan Kettering Cancer Center in 2005.

 


Prof Adrian Newland

Prof Adrian Newland

Prof Adrian Newland (who is not related to ANGLE’s Chief Executive) is Professor of Haematology at Barts Health NHS Trust and Queen Mary University of London. He is Director of Pathology for the Trust and is Clinical Director of the North East London Cancer Network. He was President of the Royal College of Pathologists from 2005 to 2008. He chairs the National Blood Transfusion Committee and is pathology lead for NHS London. He is currently chair of the Diagnostic Assessment Programme for the National Institute for Health and Clinical Excellence (NICE) and is a member of the NICE Sifting Group for cancer drugs. Adrian has been a member of the Scientific Advisory Panel of the Institute of Cancer Research from 1995 until 2003 and Chair of the London Cancer New Drugs Group since 2002. He has been a member of the National Chemotherapy Implementation Group since 2010 and a member of the Expert Reference Group on Cancer Care in London since 2009 and is a current member of the national Cancer Outcomes Advisory Group and the Human Genome Strategy Group.


Dr Clive Stanway

Dr Clive Stanway

Dr Clive Stanway is Chief Scientific Officer of Cancer Research Technology (“CRT”), the technology development and commercialisation arm of Cancer Research UK. He is an expert in cancer drug discovery and a key part of his current role is working closely with major pharmaceutical partners. Dr Stanway has extensive knowledge and experience of cancer research, detailed understanding of the drug discovery and development process, and worldwide contacts with major pharma development groups. Recently Dr Stanway has been engaged in raising the scientific profile of CRT with the pharmaceutical industry; his efforts have led to many projects being in late stage confidential discussion with potential major pharma partners and several partnerships. He has also driven an internal CRT project addressing cancer immunomodulation bringing together different technologies and expertise leading to a compound now being prepared for a Phase 1 trial. The annual research spend of Cancer Research UK is in the region of £375 million and CRT has annual revenues of approximately £50 million. Prior to becoming Chief Scientific Officer of CRT, Dr Stanway established and led the drug discovery and biotherapeutic discovery activity of CRT, which is now partnered with AstraZeneca, FORMA Therapeutics and Teva Pharmaceuticals.


Dr Harold Swerdlow

Dr Harold Swerdlow

Dr Harold Swerdlow is VP of Technology Innovation at the New York Genome Centre and is a leading expert in next-generation sequencing (NGS). In his role at the New York Genome Centre, Dr Swerdlow directs the Technology Innovation group, which is focused on novel sample-preparation methodologies for NGS including single-cell methods. Previously he was Head of Research and Development for the Wellcome Trust Sanger Institute (“the Sanger Institute”) in Cambridgeshire. In his role at the Sanger Institute, Dr Swerdlow directed the R&D department. Dr Swerdlow also helped build the Sanger Institute’s next-generation DNA-sequencing production facility into one of the world’s largest. Previously, he was the Chief Technology Officer of Dolomite Ltd., a leader in microfluidics and microfabrication. Prior to Dolomite, Dr Swerdlow was an inventor of core technology relating to NGS at Solexa Ltd., a company which he joined when it had only three employees. Dr Swerdlow helped launch Solexa’s first product, the Genome Analyzer DNA sequencing platform. At Solexa, Dr Swerdlow was responsible for instrument engineering, integration of the next-generation DNA sequencing system and early applications work, along with assisting in the development of many of the biochemical components. He was a key member of the Senior Management team that delivered Solexa’s first genome sequence, an end-to-end proof-of-principle. Following its NASDAQ listing, Solexa was acquired by Illumina Inc. for US$600 million and Solexa’s technology became the core of Illumina’s world-leading NGS products.


Dr James Reuben 3

Dr. James Reuben

Dr. Reuben is a Professor in the Department of Hematopathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas. He also serves as a Professor in the Department of Symptom Research, Division of Internal Medicine, at MD Anderson.  Reuben is a leading authority and has conducted significant research on circulating tumor cell subsets, including those with epithelial and mesenchymal phenotypes and their clinical relevance to minimal residual disease in breast cancer.

Some related publications include “Circulating tumor cells, disease progression, and survival in metastatic breast cancer in the New England Journal of Medicine”; Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients” in the British Journal of Cancer; and “Circulating tumor cells in metastatic inflammatory breast cancer” published in the Annals of Oncology.

Dr. Reuben received his PhD in immunology from McGill University in Montreal, Canada and his MBA from University of Houston, Houston, Texas. He completed his research fellowship in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center with Evan M. Hersh, MD and Emil J Freireich, MD, as mentors.


Prof Ashok Venkitaraman

Prof Ashok Venkitaraman

Prof Ashok Venkitaraman holds the Ursula Zoellner Professorship of Cancer Research at the University of Cambridge, and is Director of the Medical Research Council’s Cancer Cell Unit and Joint Director of the Medical Research Council Hutchison Cancer Research Centre. Ashok’s research has helped to elucidate the connections between chromosome instability and the genesis of epithelial cancers. He has been instrumental in establishing the Cambridge Molecular Therapeutics Programme, an initiative that links chemists, physicists, structural biologists, cancer biologists and clinicians at the University of Cambridge. Ashok has been a member of the Scientific Advisory Boards of Astex Therapeutics Ltd, Cambridge Antibody Technology (AstraZeneca affiliate), Massachusetts General Hospital Cancer Center and currently chairs the Scientific Advisory Board of Sentinel Oncology Ltd. He has also been a John H Blaffer Lecturer at M D Anderson Cancer Center. Ashok was elected a Fellow of the Academy of Medical Sciences, London, in 2001, and a member of the European Molecular Biology Organization (EMBO) European Academy, Heidelberg, in 2004.


Andrew Newland

Andrew Newland

Chief Executive

Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant. After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he led KPMG’s involvement in the IPO of the medical technology
company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG’s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in 1994. Together with ANGLE’s senior management team, Andrew has co-founded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of dstl Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.


Peggy Robinson

Peggy Robinson

US Vice President

Peggy Robinson is leading relationships with US key opinion leaders and responsible for US sales and corporate deals with major pharmaceutical and medtech companies.

Prior to joining ANGLE, Peggy was the principal of BioMark Consulting, LLC, a boutique consulting firm focused on business strategies, marketing, strategic alliances, KOL and product development of new technologies, with an emphasis on cancer diagnostics, chronic diseases and companion diagnostics.  In prior experience, Peggy was director of marketing for Veridex, a Johnson & Johnson company, and its predecessor Immunicon, responsible for the launch and market expansion of CellSearch® research products and services. Additionally, in 2011 and 2012, Peggy was Director of Strategic Alliances / Services for Veridex.  During this time she developed and implemented strategies to form collaborations for CellSearch with pharmaceutical and biotech companies.

Additional experience includes serving as Director of Systems Biology Market Development at EMD Millipore (a division of Merck Group) and as the Head of Global Marketing Communications with Siemens Medical Solutions Diagnostics, where she managed the Marketing Communications Department for the Diagnostics Division.

Complementing her comprehensive marketing expertise includes a strong clinical background as a medical technologist. Her educational background and professional credentials include a Bachelor’s degree in Biology / Medical Technology and registration as a Medical Technologist. She currently serves as the president of the Diagnostics Marketing Association (DxMA) and was awarded the Jerry R Goldsmith Award for marketing excellence, by leaders in the industry.


Jay Lewington

Chief Technology Officer

Jay joined ANGLE in 2017 with over thirty years of experience in Life Science / Medical product development, covering multi-partner collaborations, technology acquisition, IP management, project management, quality systems (ISO9001, ISO13485), clinical trials, business development and successful technology commercialisation in international markets.

 

Jay’s main expertise is the simplification and commercialisation of complex biological systems for use by non-technical operators in non-laboratory environments.  He has led several projects developing products for automated water toxicity monitoring, detection of airborne microbial and chemical contamination, farm-based instruments for diagnosis of veterinary diseases and Point of Care medical devices for the rapid diagnosis and treatment of infections.

 

Jay is a microbiologist with a Ph.D. in microbial genetics and a research background in the genetic regulation of complex metabolic pathways related to pesticide degradation and the development of antimicrobial resistance.  He has held various technical positions in large FTSE 100 (Amersham International, Merck Group, Smiths Detection) and SME start-up companies (AZUR Environmental, Enigma Diagnostics, Immunexpress), working in UK, Germany and USA.

 

During his time with Smiths Detection, Jay was responsible for the development of the business case and acquisition of the technology which established a new business unit to develop products for veterinary & clinical diagnostics, securing government and private venture investment, and resulting in a marketing & licensing agreement with a major pharmaceutical company, providing route to market for human IVD products and R&D milestone income.  Most recently Jay was CTO of Immunexpress where he led the translation of a genetic test for inflammation (sepsis) from a manual laboratory test to an automated ‘STAT lab’ platform.


Shane Booth

Shane Booth

Chief Technology Officer (retiring)

Since joining ANGLE in 1997 Shane has been active across our business areas, particularly those concerning the development and management of bioscience based companies.

Shane’s professional roots are in biomedical research. He gained his D.Phil in the Cancer Research Unit at the University of York, and from there joined the Fred Hutchinson Cancer Center in Seattle as a post-doctoral fellow. Returning to England, he spent several years as a senior researcher at the Institute for Animal Health before moving to the private sector. His research experience has encompassed chemical carcinogenesis, molecular and viral oncology, control of retrovirus infection, and agricultural applications of transgenic technology. Shane has combined his technical background with a successful career in the private sector. He has held sales, marketing and business development positions in the laboratory equipment group, Sartorius, and at Anderman, where his responsibility included development of OEM business in the diagnostics and pharmaceuticals sectors for specialised membranes produced by German group, Schleicher and Schuell. Shane’s broad experience in the biotechnology field is a key asset in the development of our portfolio companies positioned in the healthcare sector. His management of Parsortix has generated major success in its technical and commercial development.


George Hvichia

George Hvichia

Chief Scientific Officer, Parsortix Inc.

George E. Hvichia, PhD, inventor of the Parsortix technology, and Vice President of Research was trained in Bioengineering and is an expert in Microfluidics and Biochips. He has developed microdevices for industry and in academic settings.

Dr. Hvichia is the author of several peer-reviewed publications on microdevices, currently holds two US patents in field of Diagnostic Microstructures and has several more patents pending for the Parsortix technology.


Ian Griffiths

Ian Griffiths

Chief Financial Officer

Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work. He joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures, both third party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic business Parsortix.


Michael O'Brien

Michael O'Brien

Business Development Director

Michael has extensive experience of commercialising new technologies, with a solid background in strategic and operational leadership.

Michael joined ANGLE six years ago to lead a government backed technology incubator. The incubator evaluated more than 60 early stage technology companies from around the UK before selecting the highest potential start-ups and providing intense consultancy support in setting technology milestones, developing an effective business model, building collaborations and securing early customers. The technology incubator helped companies to raise in excess of £45m private investment and also put in place a number of corporate relationships to fast-track technology to market.

Prior to ANGLE, Michael gained eight years leadership experience, as Strategy and Operations director of a media company, during which time he led its merger with a sister company to form and then launch a new £4.5m company known as RadioCentre. During this time Michael chaired a number of highly successful cross industry collaboration projects.

Michael’s early career was spent at Diageo within the Corporate Strategy department where he focused on manufacturing and technology strategy, both in the UK and in operational business units in Indonesia, Australia and Singapore.

Michael has an MA in Engineering Science from the University of Cambridge and an MBA from the University of Warwick, specialising in technology commercialisation.


Martin Cooke

Head of Manufacturing and Regulatory

Martin is the Head of Manufacturing and Regulatory at Parsortix, a Chartered Engineer and holds an MEng degree in Electrical and Electronic Engineering from The University of Nottingham. He joined ANGLE in 2004 and specialises in technology commercialisation and knowledge transfer projects supporting businesses, particularly involving universities and other specialist knowledge and research centres.

Martin’s early career  was spent as a practicing design engineer  in the military, instrumentation and telecommunications sectors with particular experience in high-precision analogue measurement techniques, intrinsic safety and embedded systems. Having progressed through a number of senior technical and commercial positons, Martin became the Product Manager  of a multi-million dollar  international product family at a global telecommunications equipment provider. In this role he was responsible for product concepts, new product development and market introductions,  together with associated transition to stable manufacturing and supply. The role also encompassed on-going technical support for existing products and a large, established customer base.

Martin currently sits on the Economic and Social Research Council (ESRC) Research Committee where he is active in promoting the user application and  commercial relevance of academic research across the ESRC investment portfolio and remit.


Craig Miller

Clinical Studies Director

Craig Miller joined ANGLE in March of 2016 as the Clinical Studies Director, where he is responsible for driving the clinical development activities of ANGLE. He has over 20 years of experience in the RUO and IVD diagnostics industry, including clinical trial management, clinical data management, biostatistics, regulatory submissions, and manuscript writing and editing (Craig is a co-author on over 80 peer-reviewed publications in the field of oncology and diagnostics).

Prior to joining ANGLE, Craig was the Vice President of Clinical Development at Saladax Biomedical, where he was responsible for the design, implementation, and execution of clinical studies for the validation of novel therapeutic drug monitoring assays (MyCare®) in the field of oncology.  Before that, he was the Associate Director of Clinical Research for the Veridex Oncology Biomarkers team at Janssen R&D, a Johnson & Johnson company, where he was responsible for the design, implementation, coordination, and execution of clinical research and development trials for the evaluation, characterization, and commercialization of circulating tumor cell (CTC) assays and technologies.  During his 12 year tenure with Veridex/Janssen R&D (formerly Immunicon Corporation), Craig was instrumental in obtaining de-novo FDA clearance of the CELLSEARCH® system and associated components (i.e. CELLTRACKS® AUTOPREP® and CELLTRACKS® ANALYZER® instruments, CELLSAVE preservative tube, and CELLSEARCH® CTC Kits).

As the Director of Clinical Affairs and Biostatistics at Fujirebio Diagnostics, Inc., he played a key role in the clinical validation and FDA clearance of the MESOMARK® and ROMA® assays.  Craig started his career in diagnostics at UroCor (now Dianon Pathology, a division of LabCorp), where he held positions of increasing responsibility in Research & Development for new and innovative products in the detection, prognosis, and monitoring of urologic diseases (primarily prostate and bladder cancer).  Craig has a BS in Biochemistry from Texas A&M University.


Brad Spitz

U.S. Vice President Sales

Brad Spitz joined ANGLE in 2016 and has responsibility for sales strategies and tactics in North America.  Brad is a highly accomplished life sciences executive who has diverse experience spanning the biotech, pharmaceutical, molecular diagnostics, and oncology healthcare sectors.

Prior to joining ANGLE, Brad spent 19 years at Johnson and Johnson Medical, where he most recently served as the Western Regional Sales Director with Janssen Diagnostics.  Brad helped introduce CellSearch™, the first and only FDA approved technology for capturing, enumerating, and analyzing Circulating Tumor Cells (CTCs).  Brad drove increased utilization of CTCs and other rare cell technologies into the biotechnology and pharmaceutical sector as well as key academic research centers, NCI institutions, oncology clinics, and hospitals across Western US and Canada.  He was an active member of the senior leadership team involved in gaining product access and reimbursement, sales training, compensation planning, launching sales force automation, creating digital marketing strategy, and long term business planning.

Brad has a proven track record of leading teams and delivering results.  He has won numerous sales awards over his professional career at Janssen Diagnostics, Ortho-Clinical Diagnostics, Ethicon, and Advanced Wound Care.

Brad received his Bachelor of Science degree from the University of Wisconsin – Madison and his MBA from ELON University in North Carolina.